眾生藥業(002317.SZ):子公司獲得一項韓國專利證書、一項美國專利證書
格隆匯2月7日丨眾生藥業(002317.SZ)公佈,近日,公司控股子公司眾生睿創收到韓國知識產權局和美國專利商標局頒發的專利證書。專利名稱為一種吡啶並咪唑類化合物的晶型、鹽型及其製備方法;一種吡啶並咪唑類化合物的晶型、鹽型及其製備方法。
該授權專利是眾生睿創開發的用於預防和治療甲型流感及人禽流感的一類創新藥物ZSP1273項目的晶型專利,屬於該項目的核心專利。ZSP1273片是具有明確作用機制和全球自主知識產權的一類創新藥物,臨牀上擬用於甲型流感及人禽流感的預防和治療,是國內首個獲批、首個完成I、II期臨牀試驗的治療甲型流感的小分子RNA聚合酶抑制劑,亦是全球同靶點唯一正在開展治療單純性甲型流感III期臨牀研究的潛在Best-in-Class藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.